Cited by 58Chronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesInhalation and Respiratory Drug Delivery

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Open access
Miravitlles, Marc·2008·International Journal of Chronic Obstructive Pulmonary Disease

Abstract

AIMS: Data on differences in clinical characteristics and management of COPD in different countries and settings are limited. We aimed to characterize the profile of patients with COPD in a number of countries and their treatment in order to evaluate adherence to recommendations of international guidelines. METHOD: This was an observational, international, cross-sectional study on patients with physician-diagnosed COPD. Demographic and clinical characteristics, risk factors, and treatment were collected by their physician via an internet web-based questionnaire developed for the study. RESULTS: A total of 77 investigators from 17 countries provided data on 833 patients. The countries with the highest number of patients included were: Argentina (128), Ecuador (134), Spain (162), and Hong Kong (153). Overall, 79.3% were men and 81% former smokers, with a mean FEV1 = 42.7%, ranging from 34.3% in Hong Kong to 58.8% in Ecuador. Patients reported a mean of 1.6 exacerbations the previous year, with this frequency being significantly and negatively correlated with FEV1 (%) (r = -0.256; p < 0.0001). Treatment with short-acting bronchodilators and theophyllines was more frequent in Ecuador and Hong Kong compared with Spain and Argentina, and in patients belonging to lower socioeconomic levels (p < 0.0001 for all comparisons). Inadequacy of treatment with inhaled corticosteroids and theophyllines was high, with significant differences among countries. CONCLUSIONS: Differences in the clinical characteristics and management of COPD were significant across countries. Adherence to international guidelines appears to be low. Efforts should be made to disseminate and adapt guidelines to the socioeconomic reality of different settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/copd.s4257

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 58

Metadata

Authors
Miravitlles, M.
Affiliations
Hospital Clínic de Barcelona (ES)
Corresponding author
Miravitlles, Marc
Venue
International Journal of Chronic Obstructive Pulmonary Disease
Published
2008-12
Volume
Volume 3
Issue
4
Pages
803-814
ISSN
  • 1176-9106 (ISSN-L)
  • 1178-2005
OpenAlex
W2112674445
Cited by
58
References
42
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 5 · 2012: 1
FWCI
4.59
Type
journal article
Language
en
Open access
Locations
  • International Journal of COPD (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
chronic obstructive pulmonary disease, regional variation, clinical features, COPD management, guideline adherence, exacerbations, FEV1, short-acting bronchodilators, theophylline, inhaled corticosteroids, socioeconomic status, cross-national comparison
MeSH terms
Administration, Inhalation, Adrenal Cortex Hormones, Aged, Aged, 80 and over, Bronchodilator Agents, Cross-Sectional Studies, Drug Utilization, Female, Forced Expiratory Volume, Humans, International Cooperation, Male, Middle Aged, Practice Patterns, Physicians', Prospective Studies, Surveys and Questionnaires, Residence Characteristics, Social Class, Theophylline, Treatment Outcome, Practice Guidelines as Topic, Respiratory System Agents, Health Care Surveys, Guideline Adherence, Internet, Pulmonary Disease, Chronic Obstructive, Health Status Disparities, Healthcare Disparities, Prescription Drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review